215 related articles for article (PubMed ID: 23354655)
21. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
22. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).
Barlesi F; Gervais R; Lena H; Hureaux J; Berard H; Paillotin D; Bota S; Monnet I; Chajara A; Robinet G
Ann Oncol; 2011 Nov; 22(11):2466-2470. PubMed ID: 21321089
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.
Warwick AB; Malempati S; Krailo M; Melemed A; Gorlick R; Ames MM; Safgren SL; Adamson PC; Blaney SM
Pediatr Blood Cancer; 2013 Feb; 60(2):237-41. PubMed ID: 22745043
[TBL] [Abstract][Full Text] [Related]
24. Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma.
Huang XE; Tian GY; Cao J; Xu X; Lu YY; Wu XY; Liu J; Shi L; Xiang J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6663-7. PubMed ID: 24377585
[TBL] [Abstract][Full Text] [Related]
25. Safety, Pharmacokinetic and Clinical Activity of Intrathecal Chemotherapy With Pemetrexed via the Ommaya Reservoir for Leptomeningeal Metastases From Lung Adenocarcinoma: A Prospective Phase I Study.
Li H; Zheng S; Lin Y; Yu T; Xie Y; Jiang C; Liu X; Qian X; Yin Z
Clin Lung Cancer; 2023 Mar; 24(2):e94-e104. PubMed ID: 36588048
[TBL] [Abstract][Full Text] [Related]
26. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
[TBL] [Abstract][Full Text] [Related]
27. Pemetrexed in advanced non-small-cell lung cancer.
Fuld AD; Dragnev KH; Rigas JR
Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
[TBL] [Abstract][Full Text] [Related]
28. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung.
Omlin A; D'Addario G; Gillessen S; Cerny T; von Hessling A; Früh M
Lung Cancer; 2009 Sep; 65(3):383-4. PubMed ID: 19375814
[TBL] [Abstract][Full Text] [Related]
29. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.
Spielmann M; Martin M; Namer M; duBois A; Unger C; Dodwell DJ
Clin Breast Cancer; 2001 Apr; 2(1):47-51. PubMed ID: 11899382
[TBL] [Abstract][Full Text] [Related]
30. A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients.
Meesters RJ; Cornelissen R; van Klaveren RJ; de Jonge R; den Boer E; Lindemans J; Luider TM
Anal Bioanal Chem; 2010 Dec; 398(7-8):2943-8. PubMed ID: 20865407
[TBL] [Abstract][Full Text] [Related]
31. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
Hainsworth JD; Cebotaru CL; Kanarev V; Ciuleanu TE; Damyanov D; Stella P; Ganchev H; Pover G; Morris C; Tzekova V
J Thorac Oncol; 2010 Oct; 5(10):1630-6. PubMed ID: 20802351
[TBL] [Abstract][Full Text] [Related]
32. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
Jones RJ; Twelves CJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).
Hattori Y; Iwasaku M; Satouchi M; Nishiyama A; Korogi Y; Otsuka K; Fujita S; Katakami N; Mori M; Nishino K; Morita S; Negoro S
Jpn J Clin Oncol; 2013 Dec; 43(12):1184-9. PubMed ID: 24168805
[TBL] [Abstract][Full Text] [Related]
34. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
35. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer.
Edelman MJ; Otterson G; Leach J; Malpass T; Salgia R; Jones D; Mody TD; Govindan R
J Thorac Oncol; 2011 Apr; 6(4):786-9. PubMed ID: 21289521
[TBL] [Abstract][Full Text] [Related]
36. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
Miller DS; Blessing JA; Drake RD; Higgins R; McMeekin DS; Puneky LV; Krasner CN
Gynecol Oncol; 2009 Dec; 115(3):443-6. PubMed ID: 19804902
[TBL] [Abstract][Full Text] [Related]
37. [Long-term survival of patient with brain metastases from lung cancer treated by pemetrexed monotherapy].
Ito S; Ogawa Y; Harada H; Yamaguchi T; Munakata K
Gan To Kagaku Ryoho; 2012 May; 39(5):793-6. PubMed ID: 22584333
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
Lorusso D; Ferrandina G; Pignata S; Ludovisi M; Viganò R; Scalone S; Scollo P; Breda E; Pietragalla A; Scambia G
Ann Oncol; 2010 Jan; 21(1):61-6. PubMed ID: 19605508
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.
Cohn AL; Myers JW; Mamus S; Deur C; Nicol S; Hood K; Khan MM; Ilegbodu D; Asmar L
Invest New Drugs; 2008 Aug; 26(4):381-6. PubMed ID: 18305899
[TBL] [Abstract][Full Text] [Related]
40. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
